StockNews.com Upgrades Actinium Pharmaceuticals (NYSE:ATNM) to “Hold”

Actinium Pharmaceuticals (NYSE:ATNM) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Thursday.

ATNM has been the subject of several other research reports. Stephens assumed coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price target for the company. Maxim Group reduced their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. B. Riley cut Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $16.00 to $2.00 in a research report on Wednesday, August 7th. Finally, HC Wainwright reduced their price objective on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.43.

Actinium Pharmaceuticals Stock Up 4.7 %

ATNM stock opened at $2.00 on Thursday. Actinium Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $10.24. The business has a fifty day simple moving average of $4.62. The stock has a market capitalization of $59.57 million, a PE ratio of -1.17 and a beta of 0.20.

Actinium Pharmaceuticals (NYSE:ATNM) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. Analysts expect that Actinium Pharmaceuticals will post -1.57 EPS for the current year.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after purchasing an additional 82,113 shares during the period. Sanders Morris Harris LLC bought a new stake in Actinium Pharmaceuticals during the first quarter valued at about $78,000. Virtu Financial LLC grew its holdings in Actinium Pharmaceuticals by 319.2% during the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after purchasing an additional 62,459 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Actinium Pharmaceuticals during the second quarter valued at about $92,000. Finally, Renaissance Technologies LLC bought a new stake in Actinium Pharmaceuticals during the second quarter valued at about $142,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.